certolizumab pegol + spesolimab

Certolizumab pegol + spesolimab is a combination of two monoclonal antibody biologics, each with distinct mechanisms targeting inflammatory pathways. Certolizumab pegol is a PEGylated anti-TNFα (tumor necrosis factor alpha) monoclonal antibody fragment that blocks TNFα, reducing inflammation in autoimmune diseases such as Crohn's disease, rheumatoid arthritis, and plaque psoriasis. Spesolimab is a humanized IgG1 monoclonal antibody that acts as an interleukin-36 receptor (IL-36R) antagonist; it blocks IL-36 signaling implicated in generalized pustular psoriasis (GPP). This combination would theoretically target both TNFα-driven and IL-36–driven inflammatory processes.